About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Clues to Making Vaccine for Infant Respiratory Illness

by Kathy Jones on April 28, 2013 at 6:08 PM
Font : A-A+

 Clues to Making Vaccine for Infant Respiratory Illness

Researchers have taken a step closer to developing a vaccine for a common childhood disease thanks to an atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody.

The findings, by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, define the vulnerable shape of a critical RSV component called the fusion glycoprotein.

Advertisement

The NIAID scientists determined the fusion glycoprotein's shape as it appears before its interaction with human cells. It is this pre-fusion shape that is most vulnerable to neutralizing antibodies. Progress toward an RSV vaccine has been stalled in part because researchers did not previously know about a highly vulnerable site at the tip of the pre-fusion form of the fusion glycoprotein. Now that the structure has been solved and the site of antibody vulnerability revealed, scientists can use the new structural information to design vaccines capable of eliciting potent antibodies aimed at the target on top of the pre-fusion state of the glycoprotein.

Almost everyone is infected with RSV before turning three years of age. Most children recover quickly from such symptoms as sneezing, runny nose and cough, but the virus is a leading cause of hospitalization in children under age one. In the United States each year between 75,000 and 125,000 children in this age group are hospitalized with RSV infection. Globally, RSV infection accounts for nearly 7percent of deaths among children between the age of one month and one year. The only drug available to prevent severe RSV illness is a monoclonal antibody, palivizumab, which binds to the RSV fusion glycoprotein. In their study, the NIAID researchers showed how three antibodies that potently neutralize RSV all bind to the newly revealed site on the fusion glycoprotein of RSV. Thus, in addition to new clues for vaccine developers, the NIAID findings also provide a structural basis for how these antibodies neutralize RSV. This insight could accelerate development of these antibodies into therapies to treat or prevent severe RSV disease in very young infants, who are the most vulnerable to serious illness.
Advertisement

ARTICLE:
JS McLellan et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science DOI: 10.1126/science.1234914 (2013).

WHO:
NIAID Director Anthony S. Fauci, M.D., is available for comment. NIAID researchers Barney S. Graham, M.D., Ph.D, and Peter D. Kwong, Ph.D., NIAID Vaccine Research Center, are also available to comment on their paper.



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Research News

What Are the Effects of Smoking on Quality of Life?
Tobacco smoke contains toxic chemicals which damage lungs, weaken the immune system and cause tuberculosis.
 Brain Shape Controls Our Thoughts, Feelings, and Behaviour
Identifying an unappreciated relationship between brain shape and activity overturns the century-old paradigm emphasizing the importance of complex brain connectivity.
Eight Threats to Black Adult's Longevity
Decoding the eight factors affecting Black adults' life expectancy.
Beyond the Campus: Contrasting Realities Revealed!
Sobering truth about foot travel in the United States emerges from international statistics, highlighting the prevalence of walking on the Blacksburg campus.
Astounding Link Between Darwin's Theory and Synaptic Plasticity  Discovered!
Unveiling a hidden mechanism, proteins within brain cells exhibit newfound abilities at synapses, reinforcing Darwin's theory of adaptation and diversity in the natural world.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Clues to Making Vaccine for Infant Respiratory Illness Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests